Anyone holding out hope that a lower-cost version of the Humira rheumatoid arthritis treatment might soon become available in the U.S. can forget about it.

That’s because AbbVie (ABBV) has settled patent litigation with Boehringer Ingelheim, which will be allowed to sell a biosimilar version of the medicine as part of the deal — but not until July 2023. Boehringer had been the sole holdout among several large drug makers that previously reached such agreements, which also preclude them from marketing versions of Humira for another four years.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy